复方转移因子激发CD4^＋T淋巴细胞的实验研究

目的用化疗药物建立免疫细胞抑制的动物模型，以免疫细胞为观察指标评价复方转移因子的提高免疫细胞的能力。方法用环磷酰胺（CTX）灌胃（100mg／kg），隔天一次，连续五次，造成免疫功能抑制的动物模型，通过不同实验组用药前后免疫细胞的变化，以评价复方转移因子高、中、低（相当人用量的2、5、10倍）剂量组是否能提高实验动物的免疫细胞。结果复方转移因子能显著提高实验小鼠白细胞数量，复方转移因子低、中、高剂量组与模型组比较，P〈0．01，差别有极显著性；复方转移因子能显著提高实验小鼠淋巴细胞百分比及CD4^＋T淋巴细胞的绝对数，P〈0．01，差别有极显著性。结论复方转移因子能提高实验小鼠WBC及CD4^＋T淋巴细胞的数量，并与剂量有关。     

大蒜素对T细胞激活的影响

大蒜素在高浓度(50μg／ml)时对T细胞激活有抑制作用。但在适当浓度(3．125～12．5μg／ml)时则对T细胞激活有促进作用，这种促进作用与大蒜素抑制巨噬细胞产生NO的能力有关。大蒜素能够对抗S180细胞和艾氏暖水癌细胞产生的肿瘤免疫抑制因子对T细胞激活的抑制作用。提示大蒜素在肿瘤治疗中可能有较大的应用价值。     

幽门螺杆菌尿素酶B亚单位Th表位的免疫学特性研究

采用MHC限制性分析、ELISA方法、淋巴细胞增殖实验等方法研究幽门螺杆菌(Hp)尿素酶B亚单位(UreB)的H- 2~d限制性Th表位U_(546-561)、U_(229-244)、U_(237-251)的免疫学特性。发现抗I-E~d抗体能够抑制U_(546-561)对CD4~+T淋巴细胞的刺激,抗I-A~d抗体能够抑制U_(229-244)、U_(237-251)对CD4~+T淋巴细胞的刺激作用。U_(229-244)、U_(229-244)能刺激CD4~+T淋巴细胞分泌IL-4和IL-10,U_(237-251)刺激CD4~+T淋巴细胞分泌IFN-γ、IL-2,且U_(546-561)、U_(229-244)、U_(237-251)三个表位肽免疫BALB/c小鼠能够引起针对各自免疫多肽和rUreB的CD4~+T细胞应答。结果表明U_(546-561)为I-E~d限制性Th2表位,U_(229-244)为I-A~d限制性Th2表位、U_(237-251)为I-A~d限制性Th1表位。三个表位之间具有协同刺激效应,可以用于Hp表位疫苗的研究。     

Post‐COVID‐19 splenic infarction in a patient with chronic atrial fibrillation: A case report

We describe splenic infarction (SI), an infrequent condition, in an 82‐year‐old COVID‐19 patient with chronic atrial fibrillation (AF). COVID‐19 may cause thrombosis, and AF is a predisposing factor for splenic infarction. Suspicion of SI may be warranted in COVID‐19 patients with abdominal pain, especially if a predisposing factor exists.     

Isolated splenic metastasis of endometrial cancer 12 years after treatment: A case report and literature review

Rationale:The spleen is an uncommon metastatic organ for malignant solid tumors because of its special anatomy and microenvironment. Isolated splenic metastasis of endometrial cancer is an extremely rare clinical event, with only 17 cases reported in literature.Patient concerns:We report the case of a 58-year-old woman with abdominal distension and nausea for 7 months who had undergone surgery and chemotherapy for endometrioid adenocarcinoma 12 years previously. A space-occupying lesion in the upper pole of the spleen was observed on an abdominal ultrasound.Diagnosis:The spleen was resected, and splenic metastasis of endometrial adenocarcinoma was histologically confirmed.Interventions:Splenectomy was performed, and no lymph nodes or other metastases were observed. The patient received postoperative chemotherapy with 6 cycles of docetaxel and carboplatin.Outcomes:The patient recovered well 11 months postoperatively, with no evidence of recurrence or metastatic disease.Lesson:Since the time interval between the diagnosis of primary endometrial cancer and splenic metastasis may be very long, it may be necessary to monitor the recurrence of endometrial cancer after primary treatment.     

The bevacizumab plus oxaliplatin-based chemotherapy regimen is more suitable for metastatic colorectal cancer patients with a history of schistosomiasis: a clinical retrospective analysis

BackgroundThe basic platelet counts of schistosomiasis patients are low. If it does not meet the requirements for chemotherapy, the patient’s treatment will not be carried out, which directly affects their prognosis. Therefore the impact of treatment on platelet counts is critically important. The effects of bevacizumab plus oxaliplatin-based chemotherapy and bevacizumab plus irinotecan-based chemotherapy regimens on platelets are different but have not been determined. In order to find a more suitable plan for metastatic colorectal cancer (mCRC) patients with a history of schistosomiasis, we conducted a retrospective analysis of mCRC patients and evaluated the impact of bevacizumab on their platelets.MethodsThe medical records of all mCRC patients with a history of schistosomiasis who received oxaliplatin-based chemotherapy or irinotecan-based chemotherapy as first-line treatment for no less than 4 cycles, with or without bevacizumab from September 1, 2017, to June 30, 2019, in Kunshan Hospital were reviewed. Six-month cumulative incidence rates of splenomegaly and thrombocytopenia of chemotherapy with and without bevacizumab groups, oxaliplatin-based chemotherapy with and without bevacizumab groups, irinotecan-based chemotherapy with and without bevacizumab groups were compared from the first cycle until the completion of chemotherapy using Kaplan-Meier analysis and Log-rank test.ResultsEvaluable splenic enlargement and thrombocytopenia results were obtained from 153 mCRC patients. The 6-month cumulative incidence rates of splenomegaly (23.3% vs. 55%; P=0.01) and that of thrombocytopenia (43.8% vs. 57.5%; P=0.40) were lower in the bevacizumab group than the non-bevacizumab group, however there were no statistical differences for the rates of thrombocytopenia. For patients treated with oxaliplatin, the rates of splenomegaly (19.5% vs. 66.7%; P=0.01) and thrombocytopenia (31.7% vs. 77.2%; P=0.02) were lower in the bevacizumab-treated cohort than that in the non-bevacizumab cohort. When stratified for irinotecan, there were no statistical differences in the frequency of splenomegaly between the two groups. However, the rates of thrombocytopenia were higher in the bevacizumab-treated cohort than that in the non-bevacizumab cohort (59.4% vs. 8.7%; P=0.01).ConclusionsThe bevacizumab plus oxaliplatin-based chemotherapy regimen is safer for mCRC patients with a history of schistosomiasis, especially for patients with a lower platelet count.     

Assessment of neutrophil to lymphocyte ratio,C-reactive protein,mean platelet volume in obese,and nonobese patients with polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is associated with low-grade chronic inflammation.This was a retrospective case–control study.In the present study, the risk coefficients of neutrophil to lymphocyte ratio (NLR), high-sensitive C-reactive protein (hs-CRP), and mean platelet volume (MPV) in obese patients with PCOS were determined. This study was designed to investigate NLR, hs-CRP, and MPV levels in 68 obese patients with PCOS and 44 nonobese patients with PCOS, and our study group was matched with 47 obese and 43 nonobese controls, respectively.PCOS group had higher MPV, NLR, insulin, glucose, and HOMA-IR rates than those of the controls. Subgroup analyses revealed that the obese PCOS group had higher NLR, hs-CRP, and MPV levels compared to those of controls. The obese PCOS group had higher NLR, hs-CRP, and MPV levels compared to those of the nonobese PCOS group. The odds ratios and 95% confidence intervals of those variables (NLR, hs-CRP, MPV) were found significant (P < .05). NLR, hs-CRP, and MPV variables were found statistically significant in the analysis of receiver operating characteristics.Our study demonstrated that NLR, hs-CRP, and MPV levels are increased in patients with obese PCOS.     

链霉菌多糖的免疫学活性研究

目的 研究链霉菌多糖(SMP)对正常小鼠和免疫抑制模型小鼠的免疫调节活性.方法 通过混合淋巴细胞培养方法检测SMP对正常小鼠脾脏淋巴细胞增殖作用的影响,用酸性α-醋酸萘酯酶染色法观察免疫抑制小鼠模型外周血中T淋巴细胞的变化,以及流式细胞仪检测免疫抑制模型小鼠脾细胞中T细胞亚群Lyt2 和L3T4 的比例变化.结果 SMP可以明显促进混合淋巴细胞的增殖,并对免疫抑制模型小鼠T淋巴细胞的抑制有保护作用,还可以调节模型小鼠CD4 /CD8 的比值至正常水平.结论 SMP具有调节免疫功能的作用.     

血常规相关指标与食管癌患者治疗效果和预后的关系

炎症在恶性肿瘤的发生、进展、转移中扮演着重要的角色,在食管癌病程进展中的作用也逐渐引起人们重视。近年来食管癌患者血常规检查中相关指标与其治疗疗效和预后的关系逐步成为研究热点。现就EC患者血常规检查中一些指标与其治疗疗效和预后的关系进行概述,并主要介绍血常规中炎症复合标记物与EC患者治疗疗效和预后关系的研究进展。     

移植物抗肿瘤效应抗大肠癌的实验研究

目的通过移植物抗肿瘤效应和相关的细胞因子共同作用,建立一套综合的大肠癌辅助治疗方案。方法对BALB/C小鼠的皮下注射CT26肿瘤细胞来建立结肠癌小鼠模型,将CT26肿瘤模型鼠随机分组治疗,记录它们的存活天数、肿瘤大小、肿瘤生长抑制率。结果免疫细胞移植联合环磷酰胺(CP)治疗组的存活天数为(34.9±2.75)天,未治疗组存活天数(15.4±2.50)天(P<0.01)。联合治疗组肿瘤抑制率为94.3%。单独的CP治疗组和免疫细胞移植组肿瘤抑制率分别为99.4%和74.4%。结论免疫细胞移植存在(GVT)效应,有益于肿瘤的治疗,是潜在的细胞免疫治疗实体瘤的新方法。